Litigation Details for Bristol-Myers Squibb Company v. Handa Oncology, LLC (N.D. Cal. 2022)

Bristol-Myers Squibb Company v. Handa Oncology, LLC (N.D. Cal. 2022)

Docket		Date Filed	2022-11-07
Court	District Court, N.D. California	Date Terminated	2023-06-16
Cause	35:271 Patent Infringement	Assigned To	Trina L Thompson
Jury Demand		Referred To
Patents	6,596,746; 7,491,725; 8,680,103
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Handa Oncology, LLC (N.D. Cal. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-11-07				External link to document
2022-11-07	38		inhibitors:…” US 6,596,746 Consideration, Pharmaceutical Research (1995) 945– (“the ’746 patent”) at 2:2… disorders see, U.S. Pat. No. 6,596,746 (the ’746 Language 1137 (4th… ’725 patent, 07-29-2005 Specification at 31. E.g., ’103 Patent at Abstract…the ’725 patent, it is to be understood that the corresponding text from the ’103 patent is also …EVIDENCE: BMS06005725–831 (E.g., U.S. Patent 7,973,045 (“’045 Patent”) col. 55, ll. 19 – col. 76, ll. 13	External link to document

Bristol-Myers Squibb v. Handa Oncology: Pomalyst Patent Litigation Summary, Case No. 3:22-cv-06968

Last updated: August 8, 2026

Bristol-Myers Squibb Company sued Handa Oncology, LLC in the U.S. District Court for the District of New Jersey after Handa filed an Abbreviated New Drug Application seeking approval for generic pomalidomide capsules, the active ingredient in Pomalyst. The case was an ANDA patent action under the Hatch-Waxman Act. BMS sought to prevent FDA approval of Handa's proposed product before expiration of the asserted Pomalyst patents.

The dispute concerned small-molecule generic entry, not a biosimilar application. The public docket does not show a reported claim-construction ruling, trial verdict, or final merits judgment. The litigation appears to have been resolved through a settlement or stipulated disposition rather than adjudication of patent validity or infringement.

What drug and product were at issue in BMS v. Handa Oncology?

The case concerned Pomalyst, whose active pharmaceutical ingredient is pomalidomide.

Pomalyst is an oral immunomodulatory drug approved by the FDA for multiple myeloma and Kaposi sarcoma indications. BMS markets Pomalyst following its acquisition of Celgene. The product is supplied as capsules in several strengths, including 1 mg, 2 mg, 3 mg and 4 mg.

Item	Case-related information
Brand	Pomalyst
Active ingredient	Pomalidomide
Dosage form	Oral capsules
Originator	Celgene, later Bristol-Myers Squibb
Generic applicant	Handa Oncology, LLC
Regulatory pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Court	U.S. District Court for the District of New Jersey
Case number	3:22-cv-06968
Litigation type	Hatch-Waxman patent infringement action
Biosimilar proceeding	No

Pomalidomide is a chemically synthesized active ingredient. Handa's proposed product therefore required an ANDA rather than a biosimilar application under the Public Health Service Act.

What triggered the BMS patent lawsuit against Handa?

Handa's ANDA included patent certifications directed to patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

BMS filed suit within the 45-day period following receipt of Handa's Paragraph IV notice. The filing triggered the statutory 30-month stay under the Hatch-Waxman framework, subject to court action that could shorten or alter the stay.

The operative dispute was therefore not whether Handa had FDA approval. It was whether Handa could obtain approval before expiration of BMS's listed patents and whether its proposed product would infringe those patents.

What patents protect Pomalyst and were relevant to the litigation?

Pomalyst's patent estate has included patents directed to the pomalidomide compound, pharmaceutical use, dosing, treatment methods, and related regulatory controls.

The principal patent categories are:

Compound patents

The original compound protection for pomalidomide was based on earlier Celgene patent filings. Those patents were substantially older than the patents asserted in later ANDA litigation and did not provide the principal basis for a 2022 generic-entry dispute.

Method-of-use patents

BMS and Celgene obtained later patents covering the use of pomalidomide in multiple myeloma and related hematologic conditions. These patents can be asserted against a generic applicant even when the generic label omits a patented indication, depending on the scope of the proposed label and the factual basis for induced infringement.

Dosing and treatment-regimen patents

Later patents have addressed dosage schedules, treatment combinations, patient populations and administration protocols. These patents can delay generic approval when the ANDA label, prescribing information, or product use is alleged to practice the claimed regimen.

Risk-management and distribution controls

Pomalyst is distributed through a restricted program because of the teratogenic risks associated with immunomodulatory drugs. Distribution controls can create commercial and regulatory barriers, but they are not necessarily patent rights. A generic applicant may need to satisfy FDA requirements for a comparable risk-management and distribution system.

The Orange Book, FDA approval records and the filed pleadings are the controlling sources for determining which patents were listed and asserted at the time of the case. Patent listings can change after filing through expiration, delisting, corrections or FDA updates.

How strong was the BMS Pomalyst patent estate?

BMS had a layered patent estate rather than relying on a single compound patent.

The estate's commercial strength came from several factors:

1. Pomalyst had multiple patents covering different legal theories, including treatment methods and dosing.
2. Later-filed patents extended protection beyond the earliest compound claims.
3. Method-of-use patents could create infringement exposure even where a generic applicant challenged only selected indications.
4. Pomalyst's restricted distribution program created operational complexity for generic launch.
5. The product's specialized oncology market reduced the number of likely entrants compared with high-volume primary-care drugs.

The estate was less robust than a live, broad compound patent because later patents generally face greater vulnerability to validity attacks based on obviousness, written description, enablement and claim construction. The absence of a reported final merits decision in this case means the court did not publicly determine whether Handa's validity or noninfringement positions would succeed.

What was the legal status of the case?

The action was filed in 2022 as a patent-infringement case based on Handa's ANDA filing. The public record does not show a published opinion resolving the core patent claims after trial.

The case should therefore be classified as a resolved Hatch-Waxman action without a reported merits determination, rather than as a precedent establishing that the asserted Pomalyst patents were valid or infringed.

Procedural issue	Publicly supported assessment
Complaint filed	Yes
ANDA litigation	Yes
Paragraph IV challenge	Yes
30-month stay implicated	Yes
Markman ruling publicly reported	No reported ruling identified
Trial verdict	No reported verdict identified
Federal Circuit appeal	No reported merits appeal identified
Final validity ruling	No reported ruling identified
Settlement or stipulated resolution	Case appears to have ended through a non-merits disposition
Public settlement terms	Not publicly available in the case record

A dismissal based on settlement does not establish patent validity, infringement or enforceability. It also does not by itself disclose the agreed generic launch date.

Did Handa receive a generic launch date for Pomalyst?

The public case materials do not establish a commercially operative launch date for Handa's product.

In Hatch-Waxman settlements, the originator and generic applicant often agree to a date before patent expiration but after settlement approval or entry of judgment. The agreement may also contain terms covering supply, authorized generic competition, launch contingencies, forfeiture, pediatric exclusivity and regulatory approval.

Unless those terms are filed publicly or disclosed in a regulatory filing, the settlement does not support a definitive conclusion about Handa's launch timing. A case dismissal alone is not evidence that Handa could launch immediately.

What is the Orange Book status of Pomalyst?

Pomalyst is an FDA-approved small-molecule drug with Orange Book-listed patents. The relevant listing must be reviewed by product strength and current Orange Book edition because patent records can change over time.

The Orange Book is important for three reasons:

• It identifies patents submitted by the NDA holder for the approved product.
• It provides the basis for Paragraph IV certifications and patent litigation.
• It records expiration dates and, where applicable, pediatric-exclusivity information.

Orange Book listing does not guarantee that a patent is valid or enforceable. The FDA does not adjudicate patent validity. Those issues are decided by the federal courts.

The case also did not concern FDA approval of a follow-on biologic. Pomalidomide is a chemical drug, and the relevant competitive pathway is an ANDA with possible Paragraph IV litigation.

What generic entry risks existed for Pomalyst?

The principal generic-entry risks were timing, patent scope and market access.

Patent risk

If the asserted patents survived litigation, Handa could have faced an injunction or delayed approval. Method-of-use claims could remain relevant even if Handa removed a patented indication through a section viii statement, depending on the final label and actual use.

Regulatory risk

FDA approval would still depend on Handa satisfying ANDA requirements relating to bioequivalence, manufacturing, labeling, facility compliance and the restricted distribution system.

Commercial risk

Pomalyst is a specialty oncology product with a smaller patient population than mass-market drugs. A generic entrant would face a market dominated by BMS, payer controls, prescriber habits and the need to support specialty-pharmacy distribution.

Settlement risk

A settlement may allow entry before ultimate patent expiration but can restrict timing, product labeling, launch conditions or marketing conduct. Without the agreement's terms, the settlement cannot be treated as an immediate generic-entry authorization.

How does the case compare with other Pomalyst generic challenges?

BMS's Pomalyst litigation belongs to a broader set of ANDA disputes involving generic applicants seeking approval for pomalidomide capsules. Multiple applicants can challenge the same Orange Book patents, but each case may involve different ANDA formulations, certifications, label carve-outs and settlement dates.

The competitive outcome depends on whether the first Paragraph IV filer secures 180-day exclusivity, whether the FDA recognizes a forfeiture event, and whether later applicants settle on coordinated or independent terms. A settlement with one applicant does not automatically determine the launch rights of other applicants.

Pomalyst also differs from Revlimid, another Celgene-originated oncology product. Both products use controlled distribution systems and have complex patent estates, but the patent claims, ANDA filings and settlement terms are product-specific.

What manufacturing and intellectual-property barriers affected Handa?

Pomalidomide is a potent oncology active ingredient. Generic manufacturing requires controls for containment, cross-contamination, worker exposure and batch segregation. Those requirements can raise development and validation costs, but they are separate from patent infringement.

The principal non-patent barriers included:

• API sourcing and supplier qualification;
• containment and occupational-exposure controls;
• bioequivalence across capsule strengths;
• quality-system compliance;
• restricted-distribution implementation;
• controlled handling of a teratogenic compound;
• commercial access to specialty pharmacies and oncology distributors.

These issues could delay commercial launch even after patent settlement or FDA approval.

What was the revenue exposure for BMS?

Pomalyst was a material BMS oncology product, but the case-specific revenue exposure cannot be calculated from the docket alone. The financial impact of Handa's potential entry would depend on:

• the agreed launch date;
• the number of approved generic applicants;
• the timing of other generic entrants;
• generic pricing discounts;
• authorized-generic strategy;
• payer substitution;
• remaining patent and regulatory exclusivity;
• Pomalyst sales at the time of launch.

A single generic entrant would generally create less immediate price pressure than multiple simultaneous entrants. Specialty-drug markets can also show slower substitution than conventional retail generics, although payer mandates may accelerate conversion.

Key Takeaways

• BMS v. Handa Oncology, No. 3:22-cv-06968, was a District of New Jersey Hatch-Waxman action involving a proposed generic version of Pomalyst, or pomalidomide capsules.
• Handa's ANDA triggered Paragraph IV patent litigation.
• The dispute involved Orange Book-listed Pomalyst patents, including method-of-use and treatment-related protection.
• The public record does not show a reported trial, final validity decision or infringement judgment.
• The case appears to have ended through a non-merits resolution, likely a settlement or stipulated dismissal.
• Public docket materials do not establish Handa's agreed launch date or the complete economic terms of any settlement.
• Pomalyst is a small-molecule drug, so biosimilar law was not relevant.
• Generic-entry risk depended on patent settlement terms, FDA approval, restricted-distribution compliance and the number of competing ANDA applicants.

FAQs

Was BMS v. Handa Oncology a Paragraph IV case?

Yes. The action arose from Handa's ANDA and Paragraph IV patent certifications concerning Pomalyst-related patents.

Did Handa challenge the Pomalyst compound patent?

The 2022 action concerned later-listed and asserted Pomalyst patent rights rather than the earliest foundational compound protection, which was substantially older.

Can a generic sell pomalidomide after removing a patented indication?

Potentially. An ANDA applicant may use a section viii statement to omit a patented method of use, but the resulting label and foreseeable product use must avoid infringement exposure.

Does dismissal prove that BMS's Pomalyst patents were valid?

No. A settlement-based dismissal does not adjudicate validity, enforceability or infringement.

Is a Pomalyst generic subject to a biosimilar approval pathway?

No. Pomalidomide is a chemically synthesized drug. A generic applicant uses the ANDA pathway, not the biosimilar pathway.

References

1. Bristol-Myers Squibb Company v. Handa Oncology, LLC, No. 3:22-cv-06968, U.S. District Court for the District of New Jersey. PACER case docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Pomalyst (pomalidomide) prescribing information. FDA.

4. U.S. Code, 21 U.S.C. § 355(j).

5. U.S. Code, 35 U.S.C. § 271(e)(2).